
Opinion|Videos|June 25, 2024
Adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
Advertisement
Episodes in this series

Now Playing
- While the follow-up data for the
AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?- Efficacy of preventing RSV-related lower respiratory tract disease
- Adverse effects
- Trial limitations
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Building a Unified Approach to Cardio Kidney Metabolic Health
2
Integrating Combination Therapies for Type 2 Diabetes and CKD
3
Frequent Continuous Glucose Monitoring Linked to Greater HbA1C Reductions in Adults With T2D
4
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
5













































































































































































































